Institutional members access full text with Ovid®

Share this article on:

Delayed Presentation of Pseudoabscess Secondary to Injection of Pyrolytic Carbon-Coated Beads Bulking Agent

Berger, Mitchell B. MD, PhD; Morgan, Daniel M. MD


The article that appeared on pages 303–305 of the September/October 2012 issue should have included the following grant acknowledgment:

This research was supported by Michigan BIRCWH Career Development Program grant K12 HD001438.

The authors regret the error.

Female Pelvic Medicine & Reconstructive Surgery. 21(1):17, January/February 2015.

Female Pelvic Medicine & Reconstructive Surgery: September/October 2012 - Volume 18 - Issue 5 - p 303–305
doi: 10.1097/SPV.0b013e318264c8e0
Case Reports

Background Periurethral masses after injection of Durasphere bulking material have been previously reported to occur within 12 to 18 months of administration of the agent.

Methods We present a case report of an anterior vaginal wall mass resulting from a pseudoabscess containing Durasphere agent 5 years after injection. A literature review of urethral bulking agent complications and imaging is also provided.

Results The patient’s anterior vaginal wall mass was thought to be due to a pseudoabscess secondary to injection of bulking agent. Pelvic imaging was helpful both in identifying the mass and in surgical planning. The patient was successfully treated by outpatient transvaginal resection of the material.

Conclusions Urethral bulking agents, although generally safe and effective in the treatment of stress urinary incontinence, can lead to formation of pseudoabscesses. Although these are usually recognized within the first 18 months after injection, they may not be identified until several years later.

This report describes an atypical presentation of a pseudoabscess after urethral bulking agent injection, along with a review of the literature.

From the Pelvic Floor Research Group, Division of Gynecology, Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI.

Reprints: Mitchell B. Berger, MD, PhD, Female Pelvic Medicine and Reconstructive Surgery, Department of Obstetrics and Gynecology, University of Michigan Health System, L4000 Women’s Hospital, 1500 E Medical Center Dr, SPC 5276, Ann Arbor, MI 48109-5276. E-mail:

The authors declare that they have nothing to disclose.

Authors’ contributions:

MB Berger, manuscript writing/editing; DM Morgan: manuscript writing/editing.

Copyright © 2012 Wolters Kluwer Health, Inc. All rights reserved.